AKT1 and cancer: The AKT activator pretreatment in the OE-LHPP group noticeably reduced the levels of bax and cleaved-caspase 3 and elevated the level of bcl-2, p-AKT and p-PI3K in contrast to OE-LHPP group in cancer cells, while the inhibitor of PI3K treatment in OE-LHPP group obvious increased the expressions of bax and cleaved-caspase 3 and reduced the expression of bcl-2, p-AKT and p-PI3K compared with OE-LHPP group in SCC15 and SCC25 cells (Figure 7A, B, C, D).